Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 24, 2021		Jun. 16, 2022	Sep. 24, 2021
Net sales	$ 465.4	$ 550.4	$ 507.2		$ 874.6	$ 1,611.6
Operating Income (Loss)	(144.2)	(199.0)	(122.6)		(57.8)	(129.2)
Depreciation and amortization	(136.6)	(182.1)	(145.3)		(281.8)	(435.8)
Employee Benefits and Share-based Compensation	(0.5)	(0.5)	(2.4)		(1.7)	(8.4)
Restructuring and related charges, net	(2.2)	(3.3)	(11.7)		(9.6)	(19.5)
Non-restructuring impairment charges	0.0	0.0	0.0		0.0	(64.5)
Change in Estimate, Fresh-Start, Amount recognized	17.9	20.3
Opioid-related litigation settlement loss	0.0	0.0	125.0		0.0	125.0
Inventory Turns
Change in Estimate, Fresh-Start, Amount recognized	12.5	14.9
Petition Amount Filed with Bankruptcy Court
Bad Debt Expense, Customer Bankruptcy, Pre-Petition Amount	5.8	5.8	0.0		0.0	0.0
Specialty Brands
Restructuring and related charges, net	0.0	0.0	(0.1)		0.0	(0.1)
Specialty Generics
Net sales	161.9	188.7	147.5		287.5	462.0
Restructuring and related charges, net	0.2	0.2	0.0		(3.5)	0.0
Corporate, Non-Segment
Corporate and unallocated expenses	(15.0)	(15.9)	(20.8)	[1]	(48.2)	(69.1)	[1]
Depreciation and amortization	(148.5)	(196.9)	(168.4)		(321.8)	(506.1)
Restructuring and related charges, net	(2.2)	(3.3)	(11.0)		(9.6)	(17.5)
Separation Costs	(6.9)	(16.1)	(0.1)	[2]	(9.0)	(1.0)
Opioid-related litigation settlement loss	0.0	0.0	(125.0)		0.0	(125.0)
Operating Segments
Operating Income (Loss)	34.7	39.5	205.1		332.5	662.4
Operating Segments | Specialty Brands
Net sales	303.5	361.7	359.7		587.1	1,149.6
Operating Income (Loss)	43.7	48.2	189.9		267.2	588.6
Operating Segments | Specialty Generics
Net sales	161.9	188.7	147.5		287.5	462.0
Operating Income (Loss)	$ (9.0)	$ (8.7)	$ 15.2		$ 65.3	$ 73.8

[1] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

[2] Represents costs included in selling, general and administrative expenses, primarily related to expenses incurred related to the severance of certain former executives of the Predecessor, in addition to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.